Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipatasertib + darolutamide + androgen deprivation therapy
- Development stage
- Unknown
- Lead developer
- Big Ten Cancer Research Consortium
- Modality
- Small Molecules
- Administration
- Oral, Injection
01
Overview
This combination therapy regimen consists of the AKT inhibitor ipatasertib, the androgen receptor antagonist darolutamide, and standard androgen deprivation therapy (ADT). It is being investigated in the ADDItion trial (BTCRC-GU19-404) for the treatment of prostate cancer. The regimen targets both the androgen receptor signaling pathway and the PI3K/AKT pathway, which are often co-activated in advanced prostate cancer and contribute to treatment resistance. The study, led by Dr. David VanderWeele, evaluates the safety and efficacy of this triple combination in patients with metastatic castration-resistant prostate cancer (mCRPC) and localized high-risk prostate cancer with PI3K pathway activation.
- Other names
- ADDItion trial regimenIpatasertib + Darolutamide + ADTBTCRC-GU19-404 regimenBTCRC-GU-19-404 regimenBTCRC-GU 19-404 regimen
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)GnRHR (Gonadotropin-releasing hormone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on ipatasertib + darolutamide + androgen deprivation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipatasertib + darolutamide + androgen deprivation therapy.